The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

The FDA has approved the first new type of pain medication in more than two decades — and it’s not an opioid. The drug is Suzetrigine under the brand name Journavx. It is now FDA-approved to treat ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...